Assessment of Human Pancreas Cancer Tissue and Precursor Lesions via a Fluorophore With Inherent PDAC Selectivity

Authors

Ian R. Munhenzva, Portland State University
Connor W. Barth, Oregon Health & Science University
Martha Sibrian-Vazquez, Portland State UniversityFollow
Lei G. Wang, Oregon Health & Science UniversityFollow
Jorge O. Escobedo, Portland State UniversityFollow
Summer L. Gibbs, Oregon Health & Science UniversityFollow
Robert M. Strongin, Portland State UniversityFollow

Published In

Methods

Document Type

Citation

Publication Date

6-8-2019

Abstract

The current five-year survival rate of in vivoand ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applications, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.

Description

© 2019 Elsevier Inc. All rights reserved.

Locate the Document

https://doi.org/10.1016/j.ymeth.2019.06.008

DOI

10.1016/j.ymeth.2019.06.008

Persistent Identifier

https://archives.pdx.edu/ds/psu/28986

Citation Details

Munhenzva, I. R., Barth, C. W., Sibrian-Vazquez, M., Wang, L. G., Escobedo, J. O., Gibbs, S. L., & Strongin, R. M. (2019). Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity. Methods (San Diego, Calif.).